Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
Year: 2024
Type: article
Abstract: The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer were updated and published online in 2023, and adapted, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with early breast cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with breast cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and KSMO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early breast cancer across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling, as well as the age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.
Source: ESMO Open
Authors: K.H. Park, S. Loibl, J. Sohn, Y.H. Park, Z. Jiang, H. Tadjoedin, S. Nag, S. Saji, M. Md. Yusof, E.M.B. Villegas, E.H. Lim, Y.-S. Lu, S. Ithimakin, L.-M. Tseng, T. Dejthevaporn, T.W.-W. Chen, S.C. Lee, C. Galvez, S. Malwinder, T. Kogawa, J. Bajpai, B. Brahma, S. Wang, G. Curigliano, T. Yoshino, S.-B. Kim, G. Pentheroudakis, S.-A. Im, F. Andre, J.B. Ahn, N. Harbeck
Institutions: Korea University, Korea University Anam Hospital, German Breast Group, Yonsei University, Yonsei Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, Chinese PLA General Hospital, Dharmais Cancer Hospital, Sahyadri Hospital, Fukushima Medical University, Pantai Hospital, Kuala Lumpur, Cebu Doctors' University, Perpetual Succour Hospital, National Cancer Centre Singapore, National Taiwan University Hospital, Siriraj Hospital, Mahidol University, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, Ramathibodi Hospital, National Taiwan University, National University Cancer Institute, Singapore, St. Luke's Medical Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Homi Bhabha National Institute, Tata Memorial Hospital, Sun Yat-sen University Cancer Center, University of Milan, European Institute of Oncology, National Cancer Center Hospital East, Asan Medical Center, University of Ulsan, European Society for Medical Oncology, Seoul National University, Seoul National University Hospital, Institut Gustave Roussy, Fondation Gustave Roussy, LMU Klinikum, Ludwig-Maximilians-Universität München
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,730
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Novartis, Roche, Sanofi, Gilead Sciences, Society for Immunotherapy of Cancer, Boehringer Ingelheim Japan, Fondazione Beretta, Veracyte, Relay Therapeutics, Eisai, Astellas Pharma, European Society for Medical Oncology, Ono Pharmaceutical, Sun Pharma, Intas Pharmaceuticals, Samsung, Pfizer Japan, Chugai Pharmaceutical, Bayer Yakuhin, Institute for Oil Sands Innovation, University of Alberta, Daiichi Sankyo Europe
OpenAlex ID: W4394769738